Warning: Invalid argument supplied for foreach() in /home/globaldi/public_html/modules/mod_banners/tmpl/default.php on line 9
 

Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free ... (Centre Daily Times) PDF Print

Genentech, Inc. (NYSE:DNA) today announced that a Phase III study (ATLAS) of Tarceva® (erlotinib) in combination with Avastin® (bevacizumab) as maintenance therapy following initial treatment with Avastin plus chemotherapy in advanced non-small cell lung cancer (NSCLC) met its primary endpoint. The study was stopped early on the recommendation of an independent data safety monitoring board after ...

read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.